Septic shock is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. The incidences of septic shock and death associated with it are so high that the World Health Organization has recognized it as a Global Health Priority.
The clinical presentation of septic shock encompasses hyperlactatemia and hypotension refractory to fluid therapy along with organ dysfunction. The organ dysfunction in sepsis may present as acute respiratory distress syndrome (ARDS) which is one of the most common complications and may lead to hemodynamic instability, shock, and death. Sepsis and ARDS have a similar underlying mechanism, characterized by inflammation and endothelial dysfunction.
Management of septic shock includes the use of antibiotics for the treatment of sepsis, and fluids, inotropes, and vasopressors for the treatment of shock. While fluids, inotropes, and vasopressors can improve macrovascular circulation, improvement of microvascular circulation remains a challenge. Moreover, the adverse effects of fluids, inotropes, and vasopressors include cardiac arrhythmias, multiorgan failure, and respiratory distress.
Centhaquine (Lyfaquin®), due to its unique mechanism of action provided hemodynamic stability, significantly improved acute respiratory distress syndrome (ARDS), multiple organ dysfunction scores (MODS), and survival in clinical studies conducted in hypovolemic shock patients.
Centhaquine has already gone through extensive human studies and is in market for hypovolemic shock. We are now exploring whether centhaquine can improve clinical outcome in septic shock.
